Skip to main content

Tecentriq News (Page 2)

FDA Medwatch Alert: Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

ISSUE: FDA is alerting health care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of Keytruda (pembrolizumab) or Tecentriq...

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

South San Francisco, CA – October 18, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...

FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma

May 18, 2016 – The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Melanoma

Tecentriq patient information at Drugs.com